Related Experiment Video
Updated: Dec 25, 2025
Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
Published on: July 28, 2022
Preventive Effect of Bifidobacterium Supplementation on Neonatal Cholestasis in Preterm Neonates with Very Low Birth
Gaohong Wu1, Xiaoqian Chen1, Ningxun Cui1
1Department of Neonatology, Children's Hospital of Soochow University, Suzhou, Jiangsu 215025, China.
Insights
Bifidobacterium supplementation significantly reduced the incidence and severity of cholestasis in preterm infants with very low birth weight. This probiotic intervention offers a promising approach for managing neonatal cholestasis.
Area of Science:
- Neonatal Medicine
- Gastroenterology
- Microbiology
Background:
- Cholestasis is a serious condition in preterm neonates with limited treatment options.
- Preterm infants with very low birth weight are particularly susceptible to cholestasis.
- Current management strategies for neonatal cholestasis have notable limitations.
Purpose of the Study:
- To investigate the effects of Bifidobacterium supplementation.
- To evaluate its role in preventing and alleviating cholestasis in preterm infants.
- To assess outcomes in very low birth weight neonates receiving Bifidobacterium.
Main Methods:
- A randomized controlled trial was conducted with preterm neonates.
- Participants were assigned to either a Bifidobacterium or a control group.
- Outcomes of Bifidobacterium supplementation were compared between groups.
Main Results:
- The Bifidobacterium group showed a significantly lower incidence of neonatal cholestasis (6% vs. 22%).
- Fewer cholestasis-associated complications were observed in the Bifidobacterium group.
- Biochemical tests indicated less severe cholestasis and improved liver function in the Bifidobacterium group.
Conclusions:
- Bifidobacterium supplementation demonstrates significant preventive and beneficial effects in managing cholestasis in preterm infants.
- The probiotic appears effective in reducing cholestasis incidence and severity.
- Further research is needed to confirm long-term safety and efficacy.
Background:
Cholestasis is a common but serious clinical condition in preterm neonates. The current management for preterm neonatal cholestasis has limitations. The aim of this study was to determine effects of Bifidobacterium supplementation on the prevention and alleviation of cholestasis in preterm infants with very low birth weight.
Methods:
Preterm neonates with very low birth weight were enrolled in the Children's Hospital of Soochow University between December 2012 and December 2017. The patients were randomly assigned into Bifidobacterium and control groups, and effects of Bifidobacterium supplementation on the outcomes were compared between the two groups.
Results:
There was no significant difference in the baseline characteristics in the two groups. Notably, the proportion of cases with neonatal cholestasis was significantly lower, with fewer neonatal cholestasis-associated complications in the Bifidobacterium group compared with the control group (6% versus 22%, P < 0.01). Furthermore, the Bifidobacterium group exhibited less severe cholestasis and better improvement of the liver function than the control group as evidenced by the biochemical tests (P < 0.01). Furthermore, the Bifidobacterium group exhibited less severe cholestasis and better improvement of the liver function than the control group as evidenced by the biochemical tests (P < 0.01). Furthermore, the Bifidobacterium group exhibited less severe cholestasis and better improvement of the liver function than the control group as evidenced by the biochemical tests (days, P < 0.01). Furthermore, the Bifidobacterium group exhibited less severe cholestasis and better improvement of the liver function than the control group as evidenced by the biochemical tests (P < 0.01). Furthermore, the Bifidobacterium group exhibited less severe cholestasis and better improvement of the liver function than the control group as evidenced by the biochemical tests (P < 0.01). Furthermore, the Bifidobacterium group exhibited less severe cholestasis and better improvement of the liver function than the control group as evidenced by the biochemical tests (P < 0.01). Furthermore, the Bifidobacterium group exhibited less severe cholestasis and better improvement of the liver function than the control group as evidenced by the biochemical tests (P < 0.01). Furthermore, the Bifidobacterium group exhibited less severe cholestasis and better improvement of the liver function than the control group as evidenced by the biochemical tests (.
Conclusions:
Bifidobacterium supplementation has significantly preventive and other beneficial effects on the management of cholestasis in preterm infants with very low birth weight. Its long-term safety and effectiveness will need further investigation. This trial is registered with the Chinese Clinical Trial Registry (Registration No. ChiCTR1900022296).
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...